PVLA vs. BRO
PVLA (Palvella Therapeutics, Inc) and BRO (Brown & Brown, Inc.) are both stocks. PVLA operates in Biotechnology (Healthcare), while BRO operates in Insurance Brokers (Financial Services). Over the past year, PVLA returned 285.17% vs -21.49% for BRO. Their -0.00 correlation means they have often moved in opposite directions in the past.
Performance
PVLA vs. BRO - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, PVLA achieves a 34.50% return, which is significantly higher than BRO's -9.47% return.
PVLA
- 1D
- 1.25%
- 1M
- -4.07%
- 6M
- 76.20%
- YTD
- 34.50%
- 1Y
- 285.17%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
- ALL TIME*
- 329.97%
BRO
- 1D
- 1.96%
- 1M
- 2.54%
- 6M
- 1.20%
- YTD
- -9.47%
- 1Y
- -21.49%
- 3Y*
- 1.55%
- 5Y*
- 6.72%
- 10Y*
- 15.53%
- ALL TIME*
- 15.05%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
| $231.08M | $199.80M | $195.90M | |
| $25.27M | $30.41M | $34.17M |
PVLA vs. BRO - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | |
|---|---|---|---|
PVLA Palvella Therapeutics, Inc | 34.50% | 772.25% | -8.27% |
BRO Brown & Brown, Inc. | -9.47% | -21.37% | -2.08% |
Correlation
The correlation between PVLA and BRO is -0.08, meaning there was essentially no consistent relationship between their historical price movements. Each responded to its own set of market drivers.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | -0.08 |
Correlation (All Time) Calculated using the full available price history since Dec 16, 2024 | -0.00 |
Fundamentals
PVLA:
$2.02B
BRO:
$24.02B
PVLA:
-$3.74
BRO:
$4.77
PVLA:
$0.00
BRO:
$6.85B
PVLA:
$0.00
BRO:
$4.04B
PVLA:
-$14.75M
BRO:
$1.73B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
PVLA vs. BRO — Risk / Return Rank
PVLA
BRO
PVLA vs. BRO - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Palvella Therapeutics, Inc (PVLA) and Brown & Brown, Inc. (BRO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| PVLA | BRO | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +4.11 | ||
| Sortino ratioReturn per unit of downside risk | +4.26 | ||
| Omega ratioGain probability vs. loss probability | 1.42 | 0.89 | +0.53 |
| Calmar ratioReturn relative to maximum drawdown | 9.23 | -0.50 | +9.73 |
| Martin ratioReturn relative to average drawdown | 20.45 | -0.86 | +21.31 |
Loading charts...
Drawdowns
PVLA vs. BRO - Drawdown Comparison
The maximum PVLA drawdown since its inception was -31.48%, smaller than the maximum BRO drawdown of -55.85%. Use the drawdown chart below to compare losses from any high point for PVLA and BRO.
Loading charts...
Drawdown Indicators
| PVLA | BRO | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -31.48% | -55.85% | +24.37% |
Max Drawdown (1Y)Largest decline over 1 year | -31.11% | -43.50% | +12.39% |
Max Drawdown (3Y)Largest decline over 3 years | — | -55.85% | — |
Max Drawdown (5Y)Largest decline over 5 years | — | -55.85% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -55.85% | — |
Current DrawdownCurrent decline from peak | -10.47% | -41.72% | +31.25% |
Average DrawdownAverage peak-to-trough decline | -10.88% | -13.67% | +2.79% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 14.02% | 25.12% | -11.10% |
Volatility
PVLA vs. BRO - Volatility Comparison
Palvella Therapeutics, Inc (PVLA) has a higher volatility of 32.59% compared to Brown & Brown, Inc. (BRO) at 11.92%. This indicates that PVLA's price experiences larger fluctuations and is considered to be riskier than BRO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| PVLA | BRO | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 32.59% | 11.92% | +20.67% |
Volatility (6M)Calculated over the trailing 6-month period | 65.43% | 24.68% | +40.75% |
Volatility (1Y)Calculated over the trailing 1-year period | 84.88% | 30.15% | +54.73% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 83.99% | 25.63% | +58.36% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 83.99% | 24.05% | +59.94% |
Dividends
PVLA vs. BRO - Dividend Comparison
PVLA has not paid dividends to shareholders, while BRO's dividend yield for the trailing twelve months is around 0.90%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
BRO Brown & Brown, Inc. | 0.90% | 0.77% | 0.53% | 0.67% | 0.74% | 0.54% | 0.73% | 0.82% | 1.11% | 1.08% | 1.12% | 1.41% |
PVLA Palvella Therapeutics, Inc | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Financials
PVLA vs. BRO - Financials Comparison
This section allows you to compare key financial metrics between Palvella Therapeutics, Inc and Brown & Brown, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
PVLA and BRO have a correlation of -0.08, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
PVLA has higher volatility (32.59%) compared to BRO (11.92%). In terms of maximum drawdown, PVLA dropped -31.48% vs BRO's -55.85%.
PVLA currently has the higher Sharpe Ratio (3.39 vs -0.72), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for PVLA and BRO
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer